Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DCTH Delcath Systems Inc
- Stocks
- Healthcare
- NASDAQ: DCTH
Price (delayed)
$17.86
Market cap
$622M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.48
Enterprise value
$610.24M
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is
Highlights
Delcath Systems's debt has shrunk by 88% YoY and by 2.1% QoQ
Delcath Systems's EPS has soared by 81% YoY and by 48% from the previous quarter
Key stats
What are the main financial stats of DCTH
Market
Valuations
Earnings
Shares outstanding
34.83M
Market cap
$622M
Enterprise value
$610.24M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.44
Price to sales (P/S)
11.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.33
Revenue
$53.85M
Gross profit
$45.72M
Operating income
-$1.52M
Net income
-$14.21M
EBIT
-$14.95M
EBITDA
-$14.7M
Free cash flow
-$7.58M
Per share
Balance sheet
Liquidity
EPS
-$0.48
EPS diluted
-$0.48
Free cash flow per share
-$0.22
Book value per share
$2.4
Revenue per share
$1.55
TBVPS
$2.52
Total assets
$87.32M
Total liabilities
$7.09M
Debt
$1.02M
Equity
$80.23M
Working capital
$79.06M
Debt to equity
0.01
Current ratio
15.95
Quick ratio
13.78
Net debt/EBITDA
0.8
Margins
Efficiency
Dividend
EBITDA margin
-27.3%
Gross margin
84.9%
Net margin
-26.4%
Operating margin
-2.8%
Return on assets
-24.8%
Return on equity
-35.1%
Return on invested capital
-47.2%
Return on capital employed
-18.2%
Return on sales
-27.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DCTH stock price
How has the Delcath Systems stock price performed over time
Intraday
-1.33%
1 week
16.81%
1 month
53.57%
1 year
122.42%
YTD
48.34%
QTD
40.3%
Financial performance
How have Delcath Systems's revenue and profit performed over time
Revenue
$53.85M
Gross profit
$45.72M
Operating income
-$1.52M
Net income
-$14.21M
Gross margin
84.9%
Net margin
-26.4%
DCTH's operating margin has surged by 100% year-on-year and by 92% since the previous quarter
Delcath Systems's net margin has surged by 98% YoY and by 63% QoQ
The operating income has surged by 96% year-on-year and by 88% since the previous quarter
The net income has soared by 71% YoY and by 46% from the previous quarter
Price vs fundamentals
How does DCTH's price correlate with its fundamentals
Growth
What is Delcath Systems's growth rate over time
Valuation
What is Delcath Systems stock price valuation
P/E
N/A
P/B
7.44
P/S
11.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.33
Delcath Systems's EPS has soared by 81% YoY and by 48% from the previous quarter
DCTH's P/B is 69% lower than its last 4 quarters average of 24.0
Delcath Systems's equity has increased by 17% from the previous quarter
The price to sales (P/S) is 49% less than the 5-year quarterly average of 22.8 and 4.6% less than the last 4 quarters average of 12.2
The company's revenue rose by 45% QoQ
Efficiency
How efficient is Delcath Systems business performance
Delcath Systems's ROS has soared by 97% YoY and by 61% from the previous quarter
The ROE has soared by 90% year-on-year and by 68% since the previous quarter
The company's return on invested capital has surged by 89% YoY and by 66% QoQ
The ROA has soared by 82% YoY and by 58% QoQ
Dividends
What is DCTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DCTH.
Financial health
How did Delcath Systems financials performed over time
The total assets has soared by 142% year-on-year and by 14% since the previous quarter
DCTH's total liabilities has dropped by 67% year-on-year and by 10% since the previous quarter
Delcath Systems's debt is 99% lower than its equity
DCTH's debt to equity has shrunk by 98% YoY and by 50% QoQ
Delcath Systems's debt has shrunk by 88% YoY and by 2.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.